Recombinant Anti-IL17 x Anti-TNF Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-IL17 and anti-TNF IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can block two proinflammatory cytokines simultaneously. It is designed for the research of Rheumatoid arthritis (RA); Plaque psoriasis therapy.
There are currently no customer reviews or questions for Recombinant Anti-IL17 x Anti-TNF Bispecific Antibody (scIgG) (SCIGG-175). Click the button below to contact us or submit your feedback about this product.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRYSERVICES
PRODUCTS
PLATFORMS